Featuring perspectives from Prof Karim Fizazi and Dr Daniel George, moderated by Dr Elisabeth I Heath, including the following topics:

• Introduction (0:00)
• Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr George (3:25)
• Targeting AKT in Metastatic Prostate Cancer — Prof Fizazi (32:54)
• Tolerability and Other Practical Considerations with Capivasertib — Dr Heath (1:03:15)

CME information and select publications

Featuring perspectives from Ms Jamie Carroll, Prof Giuseppe Curigliano, Dr Marie E McDonnell and Dr Hope S Rugo, including the following topics:

• Introduction: Use of On-Body Glucose Monitoring Devices (0:00)
• Overview of Breast Cancer and Diabetes (9:39)
• PI3K/AKT/mTOR Pathway and Glucose Metabolism (19:28)
• Case Presentations — Part 1 (26:02)
• Current Data with Alpelisib, Capivasertib and Inavolisib (43:51)
• Prevention and Management of Hyperglycemia (1:02:17)
• Case Presentations — Part 2 (1:10:24)

CME information and select publications

Featuring patient case presentations by Dr Jacqueline T Brown and Dr Nazli Dizman, with commentary from Dr Matthew Milowsky, including the following topics:

• Case: A man in his mid 50s with metastatic recurrence of urothelial bladder cancer (UBC) after neoadjuvant cisplatin/gemcitabine receives first-line enfortumab vedotin (EV)/pembrolizumab (0:00)
• Case: A man in his early 50s with muscle-invasive bladder cancer (MIBC) receives adjuvant pembrolizumab, experiences disease progression and then receives EV monotherapy (12:33)
• Case: A man in his late 80s with recurrent metastatic UBC after pembrolizumab therapy for MIBC receives EV monotherapy at a reduced dose (24:07)

CME information and select publications

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics:

• Neoadjuvant immunotherapy for localized rectal cancer (0:00)
• Surveillance in neoadjuvant immunotherapy for localized rectal cancer (8:14)
• Determining a treatment strategy for resectable colon cancer (12:35)

CME information and select publications

Featuring perspectives from Dr Matthew D Galsky, Dr Shilpa Gupta, Dr Terence Friedlander and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:

• Introduction (0:00)
• Optimal Use of Anti-PD-1/PD-L1 Antibodies in Non-Muscle-Invasive Bladder Cancer — Dr Friedlander (2:27)
• Evolving Management of Muscle-Invasive Bladder Cancer — Dr Gupta (33:30)
• Current and Future Role of Novel Intravesical Therapies in Nonmetastatic Urothelial Bladder Cancer (UBC) — Prof Necchi (1:01:56)
• Emerging Utility of Circulating Tumor DNA Evaluation in Nonmetastatic UBC — Dr Galsky (1:32:47)

CME information and select publications

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics:

• Younger patient with metastatic HER2-positive, PD-L1-positive gastric cancer (0:00)
• Older patient with metastatic HER2-positive gastroesophageal (GE) cancer (8:13)
• Clinical applications for zanidatamab in GE cancer (13:58)

CME information and select publications

Featuring perspectives from Dr Paul G Richardson, including the following topics:

• Mechanism of action and pharmacology of cereblon E3 ligase modulators (0:00)
• Available efficacy data (4:54)
• Extramedullary disease (10:51)
• Side effects and toxicity (16:58)

CME information and select publications

Featuring an interview with Dr Hanny Al-Samkari, including the following topics:

• Case: A woman in her early 70s incidentally diagnosed with immune thrombocytopenia (ITP) experiences a suboptimal response to prednisone and IVIG — Bhavana (Tina) Bhatnagar, DO (0:00)
• Case: A man in his early 50s with a long history of ITP undergoes splenectomy — Neil Morganstein, MD (5:06)
• Case: A woman in her mid 50s with symptomatic iron-deficiency anemia who was found to have ITP has received corticosteroids, rituximab and IVIG — Jennifer Yannucci, MD (12:25)
• Case: A woman in her early 30s who previously received ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) and autologous stem cell transplant for Hodgkin lymphoma is diagnosed with ITP 5 years later that is refractory to high-dose prednisone, IVIG and rituximab, then romiplostim — Priya Rudolph, MD, PhD (18:19)

CME information and select publications